Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson’s disease

TA Yacoubian1, SR Slone1, AJ Harrington2, S Hamamichi3, JM Schieltz2, KA Caldwell1,2, GA Caldwell1,2 and DG Standaert1

14-3-3 proteins are important negative regulators of cell death pathways. Recent studies have revealed alterations in 14-3-3s in Parkinson’s disease (PD) and the ability of 14-3-3s to interact with α-synuclein (α-syn), a protein central to PD pathophysiology. In a transgenic α-syn mouse model, we found reduced expression of 14-3-3h, -ε, and -γ. These same isoforms prevent α-syn inclusion formation in an H4 neuroglioma cell model. Using dopaminergic cell lines stably overexpressing each 14-3-3 isoform, we found that overexpression of 14-3-3h, -ε, or -γ led to resistance to both rotenone and 1-methyl-4-phenylpyridinium, whereas other isoforms were not protective against both toxins. Inhibition of a single protective isoform, 14-3-3h, by shRNA did not increase vulnerability to neurotoxic injury, but toxicity was enhanced by broad-based inhibition of 14-3-3 action with the peptide inhibitor difopein. Using a transgenic C. elegans model of PD, we confirmed the ability of both human 14-3-3h and a C. elegans 14-3-3 homologue (ftt-2) to protect dopaminergic neurons from α-syn toxicity. Collectively, these data show a strong neuroprotective effect of enhanced 14-3-3 expression – particularly of the 14-3-3h, -ε, and -γ isoforms – in multiple cellular and animal models of PD, and point to the potential value of these proteins in the development of neuroprotective therapies for human PD.

Cell Death and Disease (2010) 1, e2; doi:10.1038/cddis.2009.4; published online 14 January 2010
Subject Category: Neuroscience

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits distribution and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.

Parkinson’s disease (PD) is a neurodegenerative disorder affecting more than four million older individuals in the most populous nations.1 There is currently no treatment that slows the degenerative process. Although the cause of most PD cases is unknown, substantial evidence points to a central role of the protein α-synuclein (α-syn). Families with point mutations or gene multiplication of α-syn exhibit autosomal dominant PD.2-6 In sporadic PD, α-syn aggregates are present in Lewy bodies.7,8 α-Syn overexpression in cellular and animal models leads to cellular injury and death,9-12 but the mechanisms of this toxicity are poorly understood.

In an effort to identify factors contributing to α-syn toxicity, we have previously evaluated alterations in gene expression in the substantia nigra (SN) of transgenic mice overexpressing human wild-type α-syn.13 We observed that among altered genes are those encoding the 14-3-3 proteins, a family of highly conserved proteins. There are seven mammalian 14-3-3 isoforms, comprising 1% of total brain protein, and these proteins participate in many cellular functions by mediating protein–protein interactions.14,15 14-3-3s have a central role in cell survival, and 14-3-3 depletion can lead to activation of proapoptotic factors.16

The observation that 14-3-3 expression was dysregulated in a rodent model of α-syn overexpression was of particular interest because of other evidence linking 14-3-3s to PD. 14-3-3s share structural homology with α-syn,17 and co-aggregate with α-syn in Lewy bodies in human PD and in a mouse PD model.18 14-3-3 and α-syn can be co-immunoprecipitated from mammalian brains,19,20 and co-immunoprecipitation is increased in PD brains.20 14-3-3h is a negative regulator of the protein parkin,20 mutation of which leads to early onset PD.21 Together, these observations support the hypothesis that α-syn toxicity can arise from sequestration of 14-3-3s, disrupting cellular signaling, and liberating proapoptotic factors. To test this hypothesis, we have examined the expression of each 14-3-3 isoform in α-syn transgenic mice and evaluated the effects of selective expression of the different isoforms in PD cellular models and in an invertebrate system. Our data reveal a potent and selective inhibition of toxicity by a subset of the 14-3-3 isoforms: 14-3-3h, -ε, and -γ.

1Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA
2Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL, USA
*Corresponding author: TA Yacoubian, Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Civitan International Research Center 525B1, 1719 6th Avenue South, Birmingham, AL 35294, USA.
Tel: + 205 996 7543; Fax: + 205 996 6580; E-mail: tyacoub@uab.edu

Keywords: 14-3-3; α-synuclein; rotenone; MPP+; Parkinson’s disease; transgenic

Abbreviations: PD, Parkinson’s disease; α-syn, α-synuclein; synT, α-syn/truncated green fluorescent protein; LDH, lactate dehydrogenase; GFP, green fluorescent protein; SN, substantia nigra; M17, SK-N-BE(2)-M17; dat-f, dopamine transporter; PPARα, peroxisome proliferator-activated receptor-α

Received 22.9.09; accepted 02.10.09; Edited by G Melino

Citation: Cell Death and Disease (2010) 1, e2. doi:10.1038/cddis.2009.4
© 2010 Macmillan Publishers Limited. All rights reserved 1350-9047/10 $32.00

www.nature.com/cddis
Results

14-3-3 isoform expression in α-syn transgenic mice. We had previously examined changes in overall gene expression in the SN of α-syn transgenic mice and found that distinct 14-3-3 isoforms were among the several hundred genes whose expression was altered in this gene array study. As this mouse model yields most prominent α-syn pathology in cortical neurons, we assessed the expression patterns of 14-3-3 isoforms in cortical homogenates from 3-month-old transgenic mice, using quantitative PCR. We found that 14-3-3y was the most significantly downregulated isoform in the cortex of the transgenic mice. This isoform was decreased by nearly 50% in transgenic mice compared to wild-type mice (Figure 1; \( P < 0.05 \)). 14-3-3y was reduced to 60% of wild type (\( P < 0.05 \)). Expression of 14-3-3y and 14-3-3z trended downward but did not reach statistical significance (\( P = 0.072 \) for 14-3-3z; \( P = 0.088 \) for 14-3-3z).

14-3-3e, -γ, and -θ reduce α-syn inclusion formation. Because previous studies have revealed that α-syn and 14-3-3s are colocalized in Lewy bodies, we asked whether increased 14-3-3 expression could affect α-syn aggregation. We used an in vitro α-syn inclusion body assay developed by McLean et al. Transfection of α-syn/truncated green fluorescent protein (synT) with synphilin results in cytoplasmic inclusions that immunostain for α-syn in about 50% of H4 neuroglioma cells (Figure 2). We co-transfected H4 cells with either empty vector or a 14-3-3 isoform along with synT and synphilin and immunostained cells against H4 cells with either empty vector or a 14-3-3 isoform. We subcloned cDNA clones for the 14-3-3 isoforms expressed from this vector are tagged with V5 and His6 epitopes at the C-terminal end. SK-N-BE(2)-M17 (M17) dopaminergic cells were transfected with each 14-3-3 vector, and stable clones were selected in the presence of G418. We created approximately 15–20 clones for each isoform. Expression of the 14-3-3 proteins was assessed by western blot analysis (Figure 3), and we chose 2–3 high-expressing clones for the experiments described below. We also created a control stable line by transfecting M17 cells with the empty pcDNA3.1/V5-His plasmid.

14-3-3 overexpression in these stably transfected lines did not affect the subcellular distribution of 14-3-3s. Immunostaining of naive M17 cells (Figure 4a) or control stable cells (Figure 4b) with an antibody against 14-3-3y revealed a predominantly cytoplasmic distribution. A similar distribution was seen when we immunostained 14-3-3y-overexpressing stable cells with either the 14-3-3y antibody (Figure 4c) or a V5 antibody (Figure 4f). Staining against 14-3-3e revealed similar subcellular distribution of 14-3-3e in naive M17 and 14-3-3e-overexpressing stable cells (data not shown). Subcellular distribution of α-syn was also not altered in 14-3-3y-overexpressing stable cells as compared to control cells (Figure 4g–j).

14-3-3y overexpression reduces rotenone toxicity. Rotenone is a pesticide that induces a parkinsonian syndrome in animals and reliably produces dose-dependent α-syn aggregation and injury. Because 14-3-3y was the isoform most altered in the cortex of α-syn transgenic mice, we first assessed the effect of 14-3-3y on vulnerability to rotenone. Control and 14-3-3y-overexpressing cells were incubated with varying concentrations of rotenone in serum-free DMEM for 24, 30, and 48 h. Cell death was assayed by lactate dehydrogenase (LDH) release into the culture media. We found that rotenone produced dose-dependent toxicity, and that 14-3-3y cells were more resistant to rotenone than were control cells over a range of rotenone doses and time points (Figure 5). The difference between control and 14-3-3y cells was most prominent at 48 h, when cell death in response to 1 μM rotenone in the 14-3-3y cells was reduced to 45% of that in control cells (Figure 5c). We confirmed these findings with a second 14-3-3y clone (Figure 5d).

As a control for artifacts that may have been introduced during the selection of stable cell lines, we also examined the effects of transient 14-3-3y transfection into naive M17 cells, using transfection with EYFP for comparison. Because this method leads to low rates of transfection, we used a different approach to measure cell death. Cells were stained against V5 or green fluorescent protein (GFP) after the treatment period, and cell injury was assessed by Hoechst 33342 staining (Invitrogen, Carlsbad, CA, USA). With the rater masked to experimental condition, the nuclei of cells that
stained for V5 or GFP were scored as normal or apoptotic. Cells transiently transfected with 14-3-3\(\gamma\)-overexpressing cells showed decreased cell death in response to rotenone (Figure 5e).

Given our results in the \(\alpha\)-syn inclusion assay, we next evaluated whether levels of insoluble \(\alpha\)-syn were reduced in 14-3-3\(\gamma\) cells as compared to control cells in response to rotenone. Rotenone increases insoluble \(\alpha\)-syn both in vitro.
and in vivo. We treated control and 14-3-3\(\gamma\) cells with 5 \(\mu\)M rotenone for 24 h and then separated cell lysates into Triton X-100 soluble and insoluble fractions. Upon rotenone treatment, insoluble \(\alpha\)-syn was dramatically increased in control cells, whereas a much smaller increase in insoluble \(\alpha\)-syn was seen in 14-3-3\(\gamma\) cells treated with rotenone (Figure 5f).

We next examined whether 14-3-3\(\gamma\) reduction by lentiviral shRNAs would result in increased rotenone toxicity to M17 cells. 14-3-3\(\gamma\) shRNA lentiviruses significantly reduced 14-3-3\(\gamma\) in M17 cells as compared to control virus with the empty pLKO.1 vector (Supplementary Figure 1a). Cells infected with 14-3-3\(\gamma\) shRNA did not show increased rotenone toxicity compared to control cells (Supplementary Figure 1b). These results were confirmed using another 14-3-3\(\gamma\) shRNA in the same lentiviral construct (data not shown).

**Differential effects of overexpression of 14-3-3 isoforms on rotenone toxicity.** Given the lack of increased rotenone toxicity with 14-3-3\(\gamma\) knockdown, we hypothesized that other 14-3-3 isoforms could compensate for the loss of 14-3-3\(\gamma\). We decided to test whether overexpression of other 14-3-3 isoforms could protect against rotenone toxicity. We found significant differences between the different isoforms in terms of their ability to protect against rotenone. Cells overexpressing 14-3-3\(\alpha\) and \(\gamma\) showed prominent reduction in rotenone-induced toxicity (Figure 6a and b). Rotenone-induced cell death at 1\(\mu\)M was reduced to 65 and 63% of control in the 14-3-3\(\alpha\) and 14-3-3\(\gamma\) lines, respectively. Overexpression of 14-3-3\(\beta\) and \(\zeta\) also provided some protection, but not to the same extent as 14-3-3\(\alpha\), \(\gamma\), or \(\delta\) (Figure 6c and d). Rotenone-induced cell death at 1\(\mu\)M was reduced to 70 and 78% of control levels in 14-3-3\(\beta\) and 14-3-3\(\delta\) cells, respectively. Differences in protection did not correlate with 14-3-3 expression levels, as 14-3-3\(\beta\) cells had higher V5 staining on western blots compared to 14-3-3\(\alpha\) and \(\delta\) (Figure 3). Results for each isoform were confirmed in 1–2 other cell clones overexpressing that isoform (data not shown).

Overexpression of 14-3-3\(\beta\) or \(\alpha\) did not provide protection against rotenone at any doses tested (Figure 6e and f). Instead, 14-3-3\(\beta\) and 14-3-3\(\alpha\) cells showed increased cell death when maintained in serum-free media (\(P<0.01\) and \(<0.001\), respectively) compared with control. In the presence of rotenone, 14-3-3\(\alpha\) cells showed increased toxicity compared to control cells, although the difference between 14-3-3\(\beta\) and control cells was less prominent. The 14-3-3\(\beta\) cells showed a nonsignificant trend toward increased toxicity in the presence of rotenone compared to control cells. These findings suggest that the 14-3-3\(\beta\) and \(\alpha\) cells were more sensitive to serum deprivation per se and that the overexpression of these proteins does not confer any specific resistance to rotenone. The results for 14-3-3\(\beta\) and \(\alpha\) were confirmed in 1–2 other cell clones overexpressing that isoform (data not shown).

**Difopein promotes rotenone toxicity.** As several 14-3-3 isoforms are protective against rotenone, we next tested whether a global competitive inhibitor of 14-3-3 function would promote rotenone toxicity. Difopein, or dimeric, fourteen-three-three peptide inhibitor, is a high-affinity 14-3-3 antagonist that disrupts 14-3-3/ligand interactions. We subcloned the difopein-EYFP sequence into the tetracycline-inducible lentiviral construct pSLIK to allow regulation of induction of difopein-EYFP in M17 cells. We infected the control-EYFP infected cells with either the difopein-EYFP lentivirus or the control-EYFP lentivirus, and infected cells were selected in the presence of hygromycin. Two days before treatment with rotenone, selected cells were treated with 10\(\mu\)g/ml doxycycline to induce difopein (or scrambled difopein) expression, and then cells were incubated with rotenone for 30 h. We found that cells expressing difopein showed increased sensitivity to rotenone compared to control cells (Figure 6g).
Differential effects of overexpression of 14-3-3 isoforms on MPP⁺ toxicity. We next tested whether the protective effects of certain 14-3-3 isoforms were restricted to rotenone or also effective against other neurotoxins that cause parkinsonian syndromes in animals. 1-Methyl-4-phenylpyridinium (MPP⁺) is the active metabolite of MPTP and causes dose-dependent cell death in dopaminergic cell lines. We tested the effects of MPP⁺ on all seven cell lines. Once again, 14-3-3y, -e, and -g overexpression reduced toxicity in response to MPP⁺ treatment for 24 h (Figure 7a–c). 14-3-3θ and -z overexpression did not show any significant protection against MPP⁺ (Figure 7d and e). 14-3-3y and -θ cells also showed similar levels of cell death compared with control cells in response to MPP⁺ (Figure 7f and g). Once again, these two sets of lines showed increased toxicity compared to control cells in serum-free media in the absence of MPP⁺.

Effects of 14-3-3s on α-syn toxicity in vivo. Although both rotenone and MPP⁺ induce α-syn aggregation, we wished to assess more directly the potential protective effects of 14-3-3s against α-syn toxicity. We turned to a C. elegans model of PD, in which human wild-type α-syn and GFP are overexpressed in dopaminergic neurons under the control of the dopamine transporter (dat-1) promoter. Transgenic C. elegans overexpressing human wild-type α-syn show a predictable loss of dopaminergic neurons as indicated by

Figure 4  Subcellular distribution of V5-tagged 14-3-3 isoforms and α-syn in stable cell lines was similar to endogenous expression in control M17 cells. (a–c) Naive M17 cells (a), control stable cells (b), and 14-3-3θ-overexpressing cells (c) were immunostained using a primary monoclonal antibody against 14-3-3θ and a Cy-3-conjugated goat anti-mouse secondary antibody to determine the cellular distribution of endogenous and overexpressed 14-3-3θ. Cells were also stained with Sytox Green to localize nuclei. 14-3-3θ Expression in all cells was seen predominantly in the cytoplasm. (d–f) These cell lines were also stained with a primary monoclonal antibody against V5 and a Cy3-conjugated goat anti-mouse secondary antibody to determine the cellular distribution of exogenous V5-tagged 14-3-3θ. V5 staining showed similar cellular distribution as 14-3-3θ in 14-3-3θ stable cells (f). No V5 staining was apparent in M17 (d) or control stable cells (e). Cells were stained with Sytox Green to visualize nuclei. (g–j) Control cells (g, h) and 14-3-3θ stable cells (i, j) were stained with an antibody against α-syn to determine subcellular localization of α-syn. Staining was apparent in both nuclear and cytoplasmic regions for both control (g) and 14-3-3θ (h) cells. Sytox Green was used to stain nuclei (i, j). Scale bar = 30 μM.
Figure 5  Overexpression of 14-3-3/y protects M17 cells from rotenone toxicity. (a–c) Cell lines stably transfected with either 14-3-3/y or empty vector were treated with varying concentrations of rotenone for 24 h (a), 30 h (b), or 48 h (c). Cell death was assayed by LDH release into the culture media. LDH release into media was normalized to total LDH release for each well. The 14-3-3/y-overexpressing line was more resistant to rotenone at several different concentrations compared to control stable cells at all time points tested. (d) At the 48 h time point, a second 14-3-3/y-overexpressing stable clone was tested to verify these results. Results reflect 2–3 independent experiments with at least two replicates per experiment. *P < 0.05, **P < 0.01, ***P < 0.001 (Bonferroni’s multiple comparison test). (e) To confirm these findings using an alternative cell death assay, we transiently transfected with V5/His-tagged 14-3-3/y construct plasmid into naive M17 cells. Control cells were transfected with GFP. At 24 h after transfection, cells were treated with rotenone at 0, 0.2, or 1 μM for 24 h. Afterwards, cells were fixed and immunostained with an antibody against V5 or GFP, followed by nuclear staining with Hoechst 33342. Nuclei of transfected cells were scored as normal or showing apoptotic changes. Rater was blind to experimental condition. n = 8 for each experimental condition. *P < 0.05, ***P < 0.001 (Bonferroni’s multiple comparison test). (f) Amount of insoluble α-syn was reduced in 14-3-3/y cells treated with 5 μM rotenone for 24 h compared to control cells. After rotenone treatment, cell lysates were separated into Triton X-100 soluble and insoluble fractions and blotted with an antibody against α-syn. Representative western blot of insoluble fractions is shown. Densitometric quantification of the multiple α-syn bands includes four independent experiments; we quantified the region between ~30 and ~70 kDa where all major bands were found. **P < 0.01 (Tukey’s multiple comparison test). Error bars reflect S.E.M.
Figure 6  Overexpression of other 14-3-3 isoforms also protects against rotenone toxicity, whereas inhibition of 14-3-3s promotes toxicity. (a–f) Cell lines stably transfected with either a 14-3-3 isoform or empty vector were treated with varying concentrations of rotenone for 48 h. Cell death was assayed by LDH release into the culture media. LDH release into media was normalized to total LDH release for each well. Lines overexpressing 14-3-3e (a), 14-3-3g (b), 14-3-3b (c), or 14-3-3z (d) were more resistant to rotenone compared to control stable cells. In contrast, overexpression of 14-3-3Z (e) and 14-3-3s (f) did not protect against rotenone and showed increased toxicity at baseline. Results reflect 2–3 independent experiments with at least two replicates per experiment. *P<0.05, **P<0.01, ***P<0.001 (Bonferroni’s multiple comparison test). Error bars reflect S.E.M.

(g) M17 cells were infected with either tetracycline-inducible difopein-EYFP lentivirus or scrambled difopein-EYFP lentivirus. After 2 days of induction by doxycycline, cells were plated and treated with increasing doses of rotenone for 30 h, and cell death was assayed by LDH release. Difopein-expressing cells were more sensitive to rotenone compared to control stable cells. *P<0.05 (least-squares means test). Results reflect three independent experiments with at least two replicates per experiment. Error bars reflect S.E.M.
alterations in cellular morphology and reduction in GFP expression.\textsuperscript{27} We created double transgenic worms in which a particular 14-3-3 isoform and α-syn were overexpressed, both under the dat-1 promoter (Figure 8). Three separate transgenic lines were created for each 14-3-3 isoform and analyzed. We focused on 14-3-3ɛ, γ, and η, the three

Figure 7 Overexpression of 14-3-3ɛ, γ, and η protects against MPP\textsuperscript{+} toxicity. Cell lines stably transfected with either a 14-3-3 isoform or an empty vector were treated with varying concentrations of MPP\textsuperscript{+} for 24 h. Cell death was assayed by LDH release into the culture media. LDH release into media was normalized to total LDH release for each well. Lines overexpressing 14-3-3ɛ (a), 14-3-3γ (b), or 14-3-3γ (c) were more resistant to MPP\textsuperscript{+} compared to control stable cells. In contrast, overexpression of 14-3-3β (d), 14-3-3ζ(e), 14-3-3η (f), or 14-3-3ρ (g) did not protect against MPP\textsuperscript{+}. Results reflect 2–3 independent experiments with at least two replicates per experiment. **P < 0.01, ***P < 0.001 (Bonferroni’s multiple comparison test). Error bars reflect S.E.M.
Figure 8  Overexpression of 14-3-3\(\gamma\) protects against dopaminergic cell loss in the \(\alpha\)-syn transgenic \(C.\ elegans\) worm model. Expression plasmids, \(P_{\text{dat}::}\) human 14-3-3\(\gamma\) and \(P_{\text{unc}::}\) mCherry, were constructed and microinjected into the gonads of \(C.\ elegans\) strain that already expresses \(\alpha\)-syn and GFP (\(P_{\text{dat}::}\) \(\alpha\)-syn; \(P_{\text{dat}::}\) GFP), and exhibits age-dependent \(\alpha\)-syn-induced degeneration in dopaminergic neurons. Similar double transgenic worms were created to overexpress human 14-3-3\(\varepsilon\), human 14-3-3\(\gamma\), or the worm 14-3-3 homologue ftt-2. In addition, a mutant ftt-2 knockout that overexpressed \(\alpha\)-syn was also created. (a) \(\alpha\)-Syn worm shows loss of dopaminergic neurons (only two CEP neurons and one ADE neuron remain) at day 7. Arrowheads show intact dopaminergic neuron cell bodies. Lined arrows indicate areas where dopaminergic neurons have degenerated. (b) Overexpression of 14-3-3\(\gamma\) in the \(\alpha\)-syn-overexpressing line protects dopaminergic neurons from \(\alpha\)-syn-induced cell death. Arrowheads show six intact dopaminergic neuron cell bodies. (c, d) 14-3-3\(\gamma\) reduced dopaminergic cell loss, but 14-3-3\(\varepsilon\) and \(\gamma\) did not. The numbers of \(\alpha\)-syn transgenic worms and \(\alpha\)-syn/14-3-3\(\gamma\) double transgenic worms that had the full complement of six anterior dopaminergic neurons were scored at day 10 (c). The percentage of intact dopaminergic neurons per worm was also scored at day 10 for \(\alpha\)-syn and \(\alpha\)-syn/14-3-3\(\gamma\) transgenic worms (d). (e, f) Overexpression (OE) of the worm 14-3-3 homologue ftt-2 also reduced dopaminergic cell death, but ftt-2 knockout did not enhance neurodegeneration. The percentage of worms that had the full complement of dopaminergic neurons (e) and the percentage of intact dopaminergic neurons per worm (f) were scored at day 10. For each experiment, three independent transgenic lines were scored, with 30 worms per line analyzed in triplicate experimental trials. Plotted data reflect the average of these three separate lines. ***\(P<0.001\) (Bonferroni's multiple comparison test). Error bars reflect standard deviation.
human isoforms that reduced neurotoxicity in response to both rotenone and MPP⁺. In worms that overexpressed only α-syn, we found that only 6.67% of the worms had all six anterior dopaminergic neurons present at 10 days, whereas 13.61% of worms that overexpressed human 14-3-3θ along with α-syn had all six dopaminergic neurons at 10 days (Figure 8c; P < 0.001). Likewise, the average number of intact dopaminergic neurons was significantly higher in the double transgenic 14-3-3θ/α-syn worms compared to α-syn worms (Figure 8d; P < 0.001). Similar results were seen when worms were analyzed at 7 days (data not shown). Transgenic 14-3-3θ or 14-3-3γ worms did not exhibit a significant change in dopaminergic neurodegeneration (Figure 8c).

We also investigated whether ftt-2, the closest C. elegans homologue to 14-3-3θ, can protect against α-syn toxicity. Of transgenic worms that overexpress ftt-2 along with α-syn, 15.19% retained all six dopaminergic neurons, compared to only 7.78% of α-syn worms, at 10 days (Figure 8e; P < 0.001). Average numbers of intact dopaminergic neurons were significantly higher in the ftt-2/α-syn double transgenic worms compared to α-syn worms (Figure 8f; P < 0.001). We also tested whether knockout of ftt-2 affected α-syn toxicity. There was no significant difference in dopaminergic cell loss between α-syn worms and α-syn/ftt-2 knockout worms at 10 days (Figure 8e and f). Semiquantitative RT-PCR was used to confirm lack of ftt-2 expression (data not shown).

**Discussion**

Using a diverse set of cellular and animal PD models, we have observed a remarkably consistent neuroprotective effect of several 14-3-3 isoforms. In α-syn transgenic mice, we report prominent mRNA downregulation of 14-3-3α, γ, and θ in the cortex, a site of intense α-syn pathology. We found that these same isoforms reduce α-syn inclusions in neuroglioma cells and attenuate rotenone and MPP⁺ toxicity in stably transfected neuroblastoma cells. Both human 14-3-3θ and its worm homologue reduced α-syn toxicity in a C. elegans model. The effects of the other isoforms were less consistent: 14-3-3β and ζ protected against rotenone but not MPP⁺, and 14-3-3η and ζ increased cell vulnerability to nonspecific insults. The consistency of these results suggests commonality in the mechanism of protection in each of these assays, and that the isoforms, although structurally similar, act on different effector systems.

Further support for the specific relationship between 14-3-3, α-syn, γ, and θ and PD pathophysiology is provided by studies of Lewy bodies in human post-mortem brain. Using isoform-specific antibodies, we observed 14-3-3α, γ, and θ in Lewy bodies, whereas the other isoforms were absent. It should be noted that we were unable to generate a 14-3-3ζ-overexpressing stable line that showed as much overexpression as lines expressing other isoforms. Therefore, it is possible that we failed to observe a broad protective effect of 14-3-3ζ because of insufficient expression. In addition, proteomic analysis of phosphorylation-dependent α-syn interactions revealed that 14-3-3ζ, γ, and θ were among those proteins that interact specifically with phosphorylated α-syn.

Although earlier studies have examined the effects of 14-3-3 proteins in PD models, few have considered the differential effects of all the distinct isoforms. One previous study showed that 14-3-3ζ overexpression is protective against MPP⁺ toxicity in PC12 cells but did not evaluate other isoforms. Studies showing interactions between 14-3-3 and α-syn have not clearly defined which isoforms are involved. Sato et al. provided the most extensive evaluation of different 14-3-3 isoforms in an analysis of 14-3-3 effects on parkin function. 14-3-3ζ was the only isoform that immuno-precipitated with parkin and inhibited its ubiquitylation activity. We found that 14-3-3ζ did not affect α-syn aggregation or reduce neurotoxicity induced by rotenone or MPP⁺ but increased sensitivity to serum deprivation. As 14-3-3θ reduces parkin function, overexpression of 14-3-3ζ could possibly be detrimental to cells by altering protein degradation. This potential mechanism does not explain our 14-3-3ζ findings, the other isoform that promoted sensitivity to stressors, as 14-3-3ζ was not found to bind parkin or alter its function. Studies showing interactions between 14-3-3s and α-syn, γ, and θ have all six dopaminergic neurons at 10 days (Figure 8e; P < 0.001). Similar results were seen in worms analyzed at 7 days (data not shown). Transgenic 14-3-3θ or 14-3-3γ worms did not exhibit a significant change in dopaminergic neurodegeneration (Figure 8c).

Currently we do not know the mechanism for the differential 14-3-3 effects observed in our studies. The different isoforms may bind to different ligands that mediate the differential neuroprotective effects. An important ligand may be α-syn. As noted above, a proteomic study showed that 14-3-3ζ, γ, and θ interacted with a phosphorylated α-syn peptide, whereas other isoforms were not detected. Here we show that in contrast to the other isoforms 14-3-3ζ, γ, and θ reduced α-syn inclusion formation. We also observed less insoluble α-syn in 14-3-3ζ cells treated with rotenone. Whether aggregation is important to α-syn toxicity, the ability of these isoforms to interact with α-syn may be key to their neuroprotective effects. Alternatively, the differential effects of 14-3-3ζ may arise from differing abilities to interact with downstream effectors. For example, 14-3-3ζ, γ, and θ interact with Bax, whereas 14-3-3ζ does not. Differential interactions of 14-3-3 proteins with other apoptotic factors could also explain their differential effects.

Although 14-3-3ζ, γ, and θ showed protection in vitro, only human 14-3-3ζ overexpression reduced toxicity in the C. elegans α-syn model. It is not clear why human 14-3-3ζ and γ were not protective in this worm model. One explanation is that 14-3-3ζ is more effective at reducing toxicity. Alternatively, C. elegans may not be able to process 14-3-3 isoforms of a different species effectively. Human 14-3-3ζ is more homologous with the C. elegans 14-3-3 orthologs than are 14-3-3ζ and γ. Indeed, we found that the worm 14-3-3 homologue ftt-2 was also effective in reducing α-syn toxicity. It is also possible that only human 14-3-3ζ can effectively interact with worm apoptotic factors.

In this study, we observed reduced RNA expression of 14-3-3ζ, γ, and θ in the α-syn transgenic mouse model. Because these are the same isoforms that were protective when overexpressed, this observation raises the possibility that reduction of 14-3-3 expression may contribute to the
progression of PD. We did attempt to examine the effect of reducing 14-3-3\(\alpha\)/mRNA levels directly through shRNA inhibition, but found that inhibition of this single isoform had no clear effect on vulnerability to rotenone. Similarly, fit-2 knockout in the C. elegans model did not promote z-syn toxicity. In both cases, other 14-3-3 isoforms could compensate for the loss of a single 14-3-3 isoform—six others in humans, and one other, par-5, in C. elegans. We did observe that the broad-spectrum 14-3-3 inhibitor, difopein, had a modest effect on sensitivity to rotenone. There are several potential explanations for the limited magnitude of this effect. First, difopein expression levels could have been limited, as higher levels are likely too toxic for cells to survive in control conditions. Second, given the differential neuroprotective effects of the 14-3-3s, the sum effect of interfering with all isoforms may not be a dramatic increase in toxicity. We are unable to test whether knockout of both fit-2 and par-5 would promote z-syn toxicity in the C. elegans model, as loss of par-5 function is embryonically lethal.\(^{15}\)

We hypothesize that z-syn can disrupt 14-3-3 function through several mechanisms that may contribute to z-syn toxicity. Previously it has been suggested that the ability of z-syn to sequester 14-3-3 isoforms would promote cell death by release of apoptotic factors normally inhibited by 14-3-3s.\(^{13}\)

We propose that z-syn also exerts its effect at a transcriptional level to reduce the expression of functional 14-3-3 proteins: decreased 14-3-3 transcription would compound effect of z-syn on 14-3-3 sequestration by preventing injured neurons from replenishing functional 14-3-3 stores. Functional genomic analysis of our microarray data has shown that genes whose expression is altered in z-syn transgenic mice are predominantly involved in transcription.\(^{13}\)

Our data point to the potential therapeutic utility of treatments that enhance 14-3-3 function or expression, especially 14-3-3\(\alpha\), \(\gamma\), and \(\delta\). Several compounds that can stimulate 14-3-3 expression have been identified, including peroxisome proliferator-activated receptor-\(\delta\) (PPAR\(\delta\)) and PPAR\(\gamma\)-ligands.\(^{36-38}\)

In a mouse stroke model, reduction of infarct volume by rosiglitazone was blocked by siRNA knockdown of 14-3-3s and restored by increasing 14-3-3s.\(^{38}\)

The actions of these compounds establish the principle that small molecules can produce potent upregulation of 14-3-3 expression, and point to the possibility of developing a useful human neuroprotective agent that uses this mechanism.

Materials and Methods

Animals. z-Syn transgenic mice originally generated by Masliah et al.\(^{39}\) were bred at Charles River Laboratories (Wilmington, MA, USA) to generate transgenic and wild-type littermates. The use of mice was supervised by the Massachusetts General Hospital Animal Resources Program in accordance with the PHS policy on Humane Care and Use of Laboratory Animals. Mice were killed by CO\(_2\) inhalation. Gender-matched wild-type and transgenic mice were killed at 3 or 9 months of age.

Quantitative PCR. RNA was extracted from the cortex of wild-type and transgenic mice and reverse transcribed into first-strand cDNA using the SuperScript II Reverse Transcriptase Kit (Invitrogen). Primers against each of the 14-3-3 isoforms were designed using Primer3 (http://frodo.wi.mit.edu). Primers against 14-3-3\(\alpha\) (NM_018753) were 5'-aaagccccgctgaacct-tc-3' (forward) and 5'-ggcgcctaa accaatattc-3' (reverse). Primers against 14-3-3\(\alpha\) (NM_006536) were 5'-ttggagttcg tttgaacctg-3' (forward) and 5'-aggagttggcagagtaag-3' (reverse). Primers against 14-3-3\(\gamma\) (NM_018781) were 5'-tttgctgctgtctgtctg-3' (forward) and 5'-aggagtcagctggtgaatg-3' (reverse). Primers against 14-3-3\(\gamma\) (NM_017139) were 5'-aaaggtcagttgattcagagt-3' (forward) and 5'-aagttttgctgtcagtctttgg-3' (reverse). Primers against 14-3-3\(\gamma\) (NM_018754) were 5'-gtctgtcct ttcctgtcagctg-3' (forward) and 5'-ttgtttgctgctgtcagtct-3' (reverse). Primers against 14-3-3\(\delta\) (NM_011740) were 5'-gcggccatcgtggttggtg-3' (forward) and 5'-ttcatcgcagtctcagttg-3' (reverse). Real-time quantitative PCR was performed as previously described.\(^{31}\) We used GAPDH (forward primer 5'-tgtaagcagcattttg-3', reverse primer 5'-tgtaagcagcattttg-3') to normalize PCR results.

z-Syn inclusion assay. H4 cells were transfected with synphilin, z-syn/synT, and either empty vector control or a 14-3-3 isoform using SuperFect transfection reagent (Qiagen, Germantown, MD, USA), as previously described.\(^{42}\) At 24 h after transfection, cells were fixed with 4% paraformaldehyde and immunostained with a monoclonal antibody against z-syn (BD Biosciences, San Diego, CA, USA) and a secondary Alexa 488-conjugated goat anti-mouse antibody (Invitrogen). All cells stained for z-syn were scored as positive or negative for z-syn inclusions, with the rater blinded to experimental condition.

Creation of stable cell lines. Each 14-3-3 isoform was subcloned into the mammalian expression vector pcDNA3.1/V5-His (Invitrogen). SK-N-BE(2)-M17 cells (ATCC, Manassas, VA, USA) were transfected with each isoform or empty vector using SuperFect, and selection for stably transfected cells was performed in the presence of G418 (Invitrogen). Some 15–20 clones for each isoform were selected for evaluation of 14-3-3 expression by western blotting.

Immunoblotting. Control and 14-3-3 stable M17 cells were sonicated for 10 s on ice in lysis buffer (150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and centrifuged at 16 000 × g for 10 min. Protein concentrations were determined by the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Samples were boiled for 5 min in 4 × DTT sample loading buffer (0.25 mM Tris-HCl (pH 6.8), 8% SDS, 200 mM DTT, 30% glycerol, Bromphenol Blue), resolved on 15% SDS-polyacrylamide gels, and transferred to PVDF membranes. Blots were blocked in 5% non-fat dry milk in TBST (25 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.1% Tween 20) for 1 h, and then incubated overnight with primary mouse monoclonal antibody against V5 (1:5000; Invitrogen), mouse monoclonal antibody against 14-3-3\(\beta\) (1:10 000; Abcam, Cambridge, MA, USA), or mouse monoclonal antibody against z-tubulin (1:1000; Sigma, St Louis, MO, USA). After three washes in TBST, blots were incubated with HRP-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) for 2 h and then washed in TBST six times for 10 min each. Blots were developed with enhanced chemiluminescence method (GE Healthcare, Piscataway, NJ, USA).

For z-syn blots of stable cell lines, cells were sonicated in lysis buffer (175 mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, protease inhibitor cocktail (Roche Diagnostics)) and incubated with 1% Triton X-100 for 30 min. After centrifugation, the supernatant was collected as the Triton X-100 soluble fraction, which contained G418 (Invitrogen). Some 15–20 clones for each isoform were selected for evaluation of 14-3-3 expression by western blotting.

Immunocytochemistry. Naive M17 cells, control stable cells, and 14-3-3-overexpressing stable cell clones were fixed in 4% paraformaldehyde and permeabilized with Triton X-100. After incubation with 1% normal goat serum, cells were incubated overnight at 4°C with a mouse monoclonal antibody against the V5 epitope tag (Invitrogen), a rabbit polyclonal antibody against 14-3-3\(\beta\) (Abcam), a mouse monoclonal antibody against 14-3-3\(\delta\) (Abcam), or a rabbit polyclonal antibody against z-syn (Cell Signaling, Danvers, MA, USA). Following washes in TBS, cells were incubated with biotinylated anti-14-3-3 antiboby and Texas Red-stained secondary antibody (Jackson ImmunoResearch) for 2 h at room temperature. Nuclei were stained with Sytox Green (Invitrogen).

LDH assay. Cells were grown in pyruvate-free DMEM for a few days before plating in 24-well collagen-treated plates. The following day, cells were treated with varying concentrations of rotenone (0, 0.04, 0.2, 1, 5, or 25 μM; Sigma) or MPP\(^+\) (0, 2, 5, or 10 mM; Sigma) in serum-free DMEM for 24, 30, or 48 h. Toxicity was determined by the lactate dehydrogenase (LDH) assay.
assayed by LDH release into media using the LDH assay kit (Roche). LDH release into media was normalized to total LDH release for each well.

RNA interference. The 14-3-3-2 plasmids, PpDat-C0, C. elegans and synphilin plasmids. We also thank Dee Parson for help with statistical analysis and Dan Carseen for review of the paper. This work was supported by an NIH NINDS K08 (NS06984-01) grant, by the American Parkinson Disease Association Postdoctoral Research Fellowship and George C Cotzias Memorial Fellowship, by the Parkinson’s Association of Alabama, and by the MGH/MIT Morris Udall Center of Excellence in PD Research.

Difopein experiments. Difopein-EYFP and scrambled difopein-EYFP were subcloned into the tetracycline-inducible lentiviral vector pSLIK.26 M17 cells were infected with the difopein-EYFP or control-EYFP viruses in the presence of polybrene. At 72h after infection, infected cells were selected for in the presence of puromycin (Mediatech, Herndon, VA, USA). Selected cells were used for doxycycline (EMD Biosciences) at 10 μg/ml to induce difopein-EYFP or control-EYFP expression.

Generation and analysis of transgenic C. elegans. Expression plasmids, Pdat-C0::14-3-3, PpDat-C0::14-3-3, and Pdat-C0::ftt-2, as well as a marker, Punc-54::mCherry, were constructed by Gateway Technology (Invitrogen) and microinjected into the gonads of C. elegans strain UA44 (batIn11; gfp) that already expresses α-syn and GFP and exhibits age-dependent α-syn-induced degeneration in the dopaminergic neurons.27 Three resulting independent transgenic lines for each strain UA113 (batEx89, Pdat-C0::14-3-3, Punc-54::mCherry), UA114 (batEx91; batEx90, PpDat-C0::14-3-3, Punc-54::mCherry), and UA115 (batEx90, Pdat-C0::14-3-3, Punc-54::mCherry), and UA131 (batEx89, PpDat-C0::14-3-3, Punc-54::mCherry) were synchronized, grown at 20°C, and analyzed for neuroprotection at days 7 and 10 (4- and 7-day-old adults). For each trial, 30 worms were transferred onto a 2% agarose pad and immobilized with 3 mM levamisole, and the six anterior synchronized, grown at 20°C for 24h, and analyzed as described above. Fluorescence microscopy was performed using a Nikon Eclipse E800 epifluorescence microscope equipped with Endow GFP HYQ filter cube (Chroma Technology, Rockingham, VT, USA), and images were captured with a Cool Snap CCD camera (Photometrics, Tucson, AZ, USA) with MetaMorph software (Molecular Devices, Downingtown, PA, USA).

Statistical analysis. GraphPad Prism 5 (GraphPad Inc., La Jolla, CA, USA) and SAS (SAS Inc., Cary, NC, USA) were used for statistical analysis of experiments. Quantitative PCR data were analyzed by two-way ANOVA, followed by post hoc least-squares means test. α-Syn aggregation experiments were analyzed by one-way ANOVA, followed by post hoc Bonferroni’s multiple comparison test. LDH assay experiments were analyzed by two-way ANOVA, followed by post hoc Bonferroni’s multiple comparison test. α-Syn blots were analyzed by one-way ANOVA, followed by post hoc Tukey’s multiple comparison test. C. elegans data were analyzed by two-way ANOVA, followed by post hoc Bonferroni’s multiple comparison test.

Conflict of interest. Talene Yacoubian and David Standaert have a pending patent application regarding the use of 14-3-3 proteins in the treatment of neurodegeneration. Sunny Slone, Adam Harrington, Shu Hamamichi, Jennifer Schiltz, Kim Caldwell, and Guy Caldwell declare no potential conflict of interest.

Acknowledgements. We wish to thank Mary Ballestad and the UAB Neuroscience Core Center (P30 NS47466) for preparation of the 14-3-3 shRNA lentiviruses and the inducible difopein lentiviruses. We wish to thank Pam McLean for providing the synT and synphilin plasmids. We also thank Dee Parson for help with statistical analysis and Dan Carseen for review of the paper. This work was supported by an NIH NINDS K08 (NS06984-01) grant, by the American Parkinson Disease Association Postdoctoral Research Fellowship and George C Cotzias Memorial Fellowship, by the Parkinson’s Association of Alabama, and by the MGH/MIT Morris Udall Center of Excellence in PD Research.
25. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem 2001; 276: 45193–45200.

26. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006; 103: 13759–13764.

27. Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 2005; 25: 3801–3812.

28. Berg D, Riss O, Bormann A. Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 2003; 54: 135.

29. McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent α-synuclein protein interactions. Mol Cell Proteomics 2008; 7: 2123–2137.

30. Chen XW, Sun SG, Cheng DB, Tian YY. Overexpression of 14-3-3 protein protects pheochromocytoma cells against 1-methyl-4-phenylpyridinium toxicity. Neurosci Bull 2006; 22: 281–287.

31. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Heremeking H et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049–6054.

32. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ Cpg island hypermethylation in human cancers. Cancer Res 2000; 60: 4353–4357.

33. Liou JY, Lee S, Gheleli D, Matijevic-Aleksić N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2008; 28: 1481–1487.

34. Nomura M, Shimizu S, Sugiyama T, Nartta M, Ito T, Matsuda H et al. 14-3-3 interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 2003; 278: 2058–2065.

35. Morton DG, Shakes DC, Nugent S, Dichoso D, Wang W, Golden A et al. The Caenorhabditis elegans par-9 gene encodes a 14-3-3 protein required for cellular asymmetry in the early embryo. Dev Biol 2002; 241: 47–58.

36. Brunelli L, Cieslik KA, Alcom JL, Vatta M, Baldini A. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-beta. Circ Res 2007; 100: e59–e71.

37. Liou JY, Lee S, Gheleli D, Matijevic-Aleksić N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta-mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2008; 28: 1481–1487.

38. Wu JS, Cheung WM, Tsaì YS, Chen YT, Fong WH, Tsaï HD et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3-Sepak ton upregulation. Circulation 2009; 119: 1124–1134.

39. Masliah E, Rockenstein E, Weinberg I, Mallory M, Hashimoto M, Takeda A et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265–1269.

40. Cooper AA, Gitter AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 2008; 313: 324–328.

Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)